Background and Purpose-Rho-kinase, an effector of RhoA, is associated with various cardiovascular diseases in circulating blood cells. However, the role of RhoA/Rho-kinase in peripheral blood mononuclear cells from patients with spontaneous aneurysmal subarachnoid hemorrhage (aSAH) has not yet been studied in relation to the severity of this disease. Therefore, we analyzed the expression and activity of RhoA as a possible biomarker in aSAH. Methods-Twenty-four patients with aSAH and 15 healthy subjects were examined. Peripheral blood mononuclear cells were collected, and RhoA activity and expression were determined by RhoA activation assay kit (G-LISA) and enzymelinked immunosorbent assay tests, respectively. The severity of aSAH was determined from the World Federation of Neurological Surgeon scale, and vasospasm was evaluated using clinical symptoms, arteriography, and sonography. Results-RhoA expression was significantly increased in peripheral blood mononuclear cells from patients on days 0, 2, and 4 after aSAH versus healthy subjects (P=0.036, 0.010, and 0.018, respectively, by U Mann-Whitney analysis). There was a significant correlation between RhoA expression and injury severity on days 2 and 4 (Spearman test, day 2: r=0. 682, n=14, P=0.007; day 4: r=0.721, n=14, P=0.004). No significant correlation was observed on day 0 (day 0: r=0.131, n=6, P=0.805). Active RhoA was not significantly different in patients and healthy subjects on days 0, 2, and 4 (P=0.243, 0.222, and 0.600, respectively) nor did it increase significantly on days 0 and 2 in patients with vasospasm versus patients without vasospasm (P=0.064 and 0.519, respectively). In contrast, active RhoA was significantly higher on day 4 in patients who developed vasospasm versus patients without vasospasm (P=0.028). Conclusions-Our preliminary results indicate that RhoA expression and activity in peripheral blood mononuclear cells might be related with aSAH severity and cerebral vasospasm. RhoA is a potential biomarker of the risks associated with aSAH.
M icrovascular constriction and inflammation, more specifically blood cell-endothelium interaction, seem to play a critical role in sustained cerebral vasospasm (CV) occurring 3 to 14 days after aneurysmal subarachnoid hemorrhage (aSAH). 1 Higher levels of molecules that facilitate blood cell-endothelium interaction have been found in human cerebral spinal fluid and serum. 2 RhoA is a monomeric G-protein that participates in the regulation of several cell functions, such as contraction, migration, and adhesion. 3 RhoA can be present in inactive (GDPbound) and active (GTP-bound) conformational states. Once activated, RhoA turns on its effector proteins, such as Rhoassociated kinase (ROCK). Although activation of ROCK in human peripheral blood cells is associated with cardiovascular pathologies, such as acute ischemic stroke, 4 pulmonary arterial hypertension, 5 and cardiovascular disease, 6 its role in aSAH has not been evaluated. Because ROCK can be activated by a wide range of stimuli in addition to RhoA, we have analyzed RhoA in peripheral blood mononuclear cells (PBMCs) from patients with aSAH. To the best of our knowledge, this is the first study that explores the role of RhoA in PBMCs in patients with aSAH.
Methods

Patients and Control Subjects
We cannot make our data, analytic methods, and study materials available to other researchers because the privacy of our patients is protected by institutional review board regulations. A total of
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39 individuals were studied, of which 24 were patients who had experienced severe aSAH (Fisher 3 and Fisher 4). A group of healthy controls (n=15) was also evaluated (Table) . This study was approved by the Ethics Committee of the Virgen del Rocío University Hospital, and all relatives and legal representatives gave their informed consent in writing. Because the origin of the samples is human, the ethical research principles were fulfilled following the Helsinki Declaration and the Belmont report. The study also adhered to 2 legal provisions governing human research and the Spanish Organic Law 15/1999 for the Regulation of Automated Processing of Personal Data.
aSAH Severity
Glasgow Coma Scale, Hunt-Hess, and World Federation of Neurological Surgeon were used to evaluate patients during the first 24 hours after hospital admission, after performing hemodynamic and metabolic resuscitation to rule out pharmacological influence, such as sedation.
PBMCs Collection
Mononuclear cells were isolated from human blood samples drawn from the arterial line of patients with aSAH to measure invasive arterial pressure and obtain other samples (conventional laboratory measurements and arterial blood gases). Samples for this research were obtained at hospital admission (day 0), at 48 hours (day 2), and at 96 hours (day 4). A total of 8 mL of blood was collected in cell preparation tubes (BD Diagnostic) and centrifuged at 1800g for 20 minutes at room temperature. After centrifugation, cells were recovered from a whitish layer just below the plasma column, washed in 2 mL of PBS at 4°C, and centrifuged again at 300g for 10 minutes. The whole supernatant was removed, and the pellet was frozen at −80°C until analysis. The hospital guidelines established for handling of blood samples of patients were followed.
RhoA Expression and Activity Measurement
Total RhoA was determined using the colorimetric Total RhoA enzyme-linked immunosorbent assay biochem kit (Cytoskeleton). Cells were homogenized in lysis buffer. Protein concentration was determined according to the manufacturer's protocol, and extracts were equalized to ≈1 mg/mL of proteins. Total RhoA was detected using indirect immunodetection followed by a colorimetric reaction measured by absorbance at 490 nm. The resulting measurements were extrapolated to the standard curve developed in each experiment. Active RhoA was determined with the colorimetric RhoA activation assay (G-LISA) (Cytoskeleton) using the same conditions. When indicated, hypertensive patients were excluded from RhoA analysis given findings that showed elevated levels of ROCK activation in these patients. 6 Each set of data is expressed as mean±SEM for every determination, performed in duplicate.
Diagnosis of Vasospasm
Vasospasm diagnosis was performed via clinical symptoms, transcranial Doppler, or angiography between days 0 to 8 after the bleeding event. Using digital subtraction angiography, vasospasm was regarded as moderate if lumen reduction was between 25% and 49% and severe if arterial narrowing reached ≥50%. Transcranial Doppler exploration (Doppler Multidop-P, DWL) was performed with a 2-MHz ultrasound probe through the temporal window, in both hemispheres. The first study was performed on the third day, and every day between days 3 and 14 after aSAH, and beyond this date if transcranial Doppler recording was not normal. Transcranial Doppler vasospasm was defined as a mean flow velocity (MV) in any vessel of anterior cerebral circulation ≥120 cm/s. If the MV obtained reached 120 cm/s, the Lindegaard index was calculated by simultaneously recording the homolateral extracranial internal carotid artery at submandibular site and the MV of middle cerebral artery. MV middle cerebral artery/MV extracranial internal carotid artery ratio of >3 was classified as sonographic vasospasm. Patients with MV >120 cm/s and Lindegaard index <3 were diagnosed with increased cerebral blood flow. Symptomatic vasospasm was defined as worsening of the level of consciousness of ≥2 points on the Glasgow Coma Scale, or by the appearance of a focal defect between days 4 and 14 after the bleeding event, not attributable to rebleeding, hematoma, hydrocephalia, metabolic alterations, infection, or oversedation. Delayed cerebral ischemia was defined as symptomatic vasospasm or the appearance of new infarction on head computed tomography or magnetic resonance, after having differentiated infarction from other causes of hypodensity images. Investigators and laboratory personnel performing the tests were blinded to the clinical course.
Statistical Analysis
A descriptive analysis was performed using qualitative variables, represented in the tables as absolute frequencies and percentages. After applying Shapiro-Wilks tests, quantitative variables were expressed using median and SD or mean interquartile range (P 25 -P 75 ), depending on whether or not they followed a normal distribution. Comparisons of means of quantitative variables between subgroups were performed using Student t test for independent samples or the nonparametric Mann-Whitney U test if variables presented a non-normal distribution. Correlation analysis was performed using Spearman test. P<0.05 was considered significant. All statistical analyses were conducted using software from the Statistical Package for the Social Sciences (version 24.0, Chicago, IL).
Results
RhoA Expression and Its Relationship With Injury Severity
RhoA expression (total RhoA) was significantly increased in patient PBMCs on days 0, 2, and 4 (day 0: 6.322 [4. [0.763-5.322; Figure 1A ). Similar results were obtained when hypertensive patients (n=11) were excluded from the analysis (RhoA expression at day 0, P=0.072; day 2, P=0.027; and day 4, P=0.031). Although there was no significant correlation on day 0 between RhoA expression in patients and injury severity, as assessed by the World Federation of Neurological Surgeon (Spearman test, day 0: r=0.131, n=6, P=0.805; Figure 1B) , a significant correlation was observed on days 2 and 4 (day 2: r=0.682, n=14, P=0.007; day 4: r=0.721, n=14, P=0.004; Figure 1C and 1D) . Figure 2B ).
Activated RhoA and Its Relationship With CV
Discussion
A key finding in the present study is that the amount of RhoA protein (total RhoA) was significantly increased in patients with aSAH on admission day (day 0) versus healthy controls. Considering that patients are hospitalized immediately after bleeding and that the events determining the precise moment of aneurysm rupture are not known, we posit that the increase in RhoA expression may be involved in this phenomenon. On days 2 and 4, we observed a significant correlation between RhoA expression in aSAH and injury severity. Hence, RhoA level in PBMCs, together with other clinical approaches, could be used as a complementary and observer-independent method to evaluate injury severity after hospital admission. However, the elevated level of RhoA in patients on days 0, 2, and 4 may facilitate its activation in response to chemical or physical stimuli triggered by aSAH. In support of this hypothesis, we found that activated RhoA is increased on day 4 in PBMCs from patients who finally developed vasospasm versus patients without vasospasm. Given that CV begins ≈3 days after aneurysm rupture, activated RhoA could be used in tandem with other biomarkers to predict vasospasm in these patients. Evidence has shown that ROCK activity is increased in patients with cardiovascular diseases, 6 a group similar to our subjects. Because ROCK is a RhoA effector, an increase in RhoA activity should be expected in our patients. However, this is not our case, suggesting that Figure 1 . RhoA expression in control subjects and patients on days 0, 2, and 4 after aneurysmal subarachnoid hemorrhage (aSAH). A, Total RhoA expression was significantly increased on days 0, 2, and 4 in aSAH vs healthy subjects (U Mann-Whitney, day 0: n ctrl =15, n patients =6; day 2: n ctrl =15, n patients =14; day 4: n ctrl =15, n patients =14 
